Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 07 tags : Phase 3 save search
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Published: 2021-06-07 (Crawled : 23:00) - globenewswire.com
HOOK | $0.7998 5.24% 4.98% 480K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: -20.15%
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.03%
H: 0.25%
C: 0.1%
phase 1 therapy cancer phase 3 phase 2 t-cell
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
ALLK | $1.055 -2.32% -2.37% 300K
|
Health Technology
|
| O: -0.12%
H: 4.21%
C: 2.01%
phase 2 clinical trials phase 2/3 phase 3 trial enroll
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
Published: 2021-06-07 (Crawled : 17:00) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: 0.06%
H: 1.26%
C: 0.72%
EXEL 4 | $22.83 0.57% 0.57% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.85%
C: -1.03%
results cancer phase 3 trial
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 2.49% 37K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
AUPH | $5.01 -0.6% -0.6% 850K
|
Health Technology
|
| O: 1.76%
H: 2.36%
C: 1.42%
phase 3
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
BYSI | $1.805 2.56% 2.49% 37K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 11:00) - biospace.com/
MRK | $125.06 -0.9% 0.0% 5.6M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.81%
treatment renal phase 3 trial keytruda cell carcinoma
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $53.23 -0.37% -0.38% 1.5M
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.